Top 10 Net Payout Yield Stocks To Own For 2015

Top hedge fund managers look beyond the United States to find the best investment opportunities. And we do, too. Indeed, my latest recommendation is a Japanese stock, says Mark Skousen, editor of Hedge Fund Trader Alert.

Let me make the macroeconomic case first, starting with valuations. Japanese stocks are cheap. If the Nikkei 225 rose 70%, it still would be cheaper than the S&P 500 on a price-to-book value basis. In fact, the Tokyo market could triple from here and it would still be no higher than it was in 1989!

You shouldn’t fight the Fed—and the same is true of Japan’s central bank. The Bank of Japan is in an ultra-accommodative mode right now, determined to weaken the yen until Japanese inflation hits 2%. That won’t be anytime soon. Right now, Japanese consumer prices are stagnant.

A weaker yen strengthens exporters, the backbone of the Japanese economy. As Japanese cars, televisions, machinery, and electronics are priced cheaper overseas, sales will rise…and so will corporate profits.

Top 10 Net Payout Yield Stocks To Own For 2015: Koninklijke Ahold NV (AHONY)

Koninklijke Ahold N.V. (Ahold), incorporated on April 29, 1920, is engaged in the operation of retail food stores in the United States and Europe through subsidiaries and joint ventures. Ahold’s retail operations are presented in four segments: Stop & Shop/Giant-Landover, Giant-Carlisle, Albert Heijn and Albert/Hypernova. During the fiscal year ended January 3, 2010 (fiscal 2009), it operated 2,909 stores. On February 8, 2010, Ahold’s Giant-Carlisle acquired 25 stores from Ukrop’s Super Markets.

Franchisees operated 783 of the Albert Heijn, Etos and Gall & Gall stores, 463 of which were either owned by the franchisees or leased independently from Ahold. Of the 2,446 stores, 20% were company-owned and 80% were leased. Ahold’s stores range in size from 20 to over 10,000 square meters. Albert Heijn is a food retailer in the Netherlands. Etos is a health and beauty retailer in the Netherlands. Gall & Gall is a wine and liquor specialist in the Netherlands. Stop & Shop is a supermarket brand, operating in six states in the northeast United States. Giant-Landover is a supermarket brand, operating in four states in the mid-Atlantic United States. Peapod is an online grocery delivery service working in partnership with Stop & Shop and Giant-Landover. It also serves the metropolitan areas of Chicago, Illinois; Milwaukee and Madison, Wisconsin, and the northern areas of Indiana.

Advisors’ Opinion:

  • [By Rich Duprey]

    As mentioned, Kroger is still swallowing Harris Teeter and has said it needs time to make more acquisitions. Royal Ahold (NASDAQOTH: AHONY  ) is also said to be leery about doing large acquisitions these days, while Cerberus recently finished acquiring the Albertsons and Acme chains from SUPERVALU (NYSE: SVU  )  for $3.3 billion.

Top 10 Net Payout Yield Stocks To Own For 2015: TCW Strategic Income Fund Inc (TSI)

TCW Strategic Income Fund, Inc. (the Fund), formerly TCW Convertible Securities Fund, Inc., incorporated on January 13, 1987, is a diversified closed-end investment management company. The Fund’s investment objective is to seek a total return consisting of current income and capital appreciation by investing in convertible securities, marketable equity securities, investment-grade debt securities, high-yield debt securities, options, and securities issued or guaranteed by the United States Government, its agencies and instrumentalities (U.S. Government Securities). The Fund also invests in repurchase agreements, mortgage-related securities, asset-backed securities, money market securities and other securities.

The Fund may invest in repurchase agreements secured by U.S. Government Securities. The Fund invests in sectors, such as financial services, aerospace and defense, airlines, automobiles, banking, commercial services, electric utilities, insurance, media, utilities, biotechnology and chemicals. The Fund’s investment advisor is TCW Investment Management Company.

Advisors’ Opinion:

  • [By Dividends4Life]

    According to a Gabelli Funds report, managed distribution policies offer several advantages, including:1. Lower difference between the fund’s market price and its NAV per share.2. Provides support during periods when the stock market is in a decline.3. Provides a measurable performance target for the investment adviser.Below are several high-yield funds from CEFA that have a managed distribution policy (yields as of December 16):Aberdeen Australia Eqty (IAF)- Distribution Yield: 10.4%- Income Yield: 346%Bexil Advisers LLC  (DNI)- Distribution Yield: 11.1%- Income Yield: 3.56%BlackRock En Capital&Inc (CII)- Distribution Yield: 8.78%- Income Yield: 2.34%Cornerstone Strat Value (CLM)- Distribution Yield: 18.77%- Income Yield: 1.83%Cornerstone Total Return (CRF)- Distribution Yield: 19.10%- Income Yield: 0.85%Delaware Inv Div & Inc (DDF)- Distribution Yield: 6.70%- Income Yield: 5.26%Gabelli Equity Trust (GAB)- Distribution Yield: 7.58%- Income Yield: 1.54%Gabelli Utility Trust (GUT)- Distribution Yield: 9.45%- Income Yield: 2.84%MFS Special Value Trust (MFV)- Distribution Yield: 9.60%- Income Yield: 5.73%Nuveen Tx-Adv TR Strat (JTA)- Distribution Yield: 6.70%- Income Yield: 3.12%TCW Strategic Income (TSI)- Distribution Yield: 10.54%- Income Yield: 7.88%Zweig Total Return (ZTR)- Distribution Yield: 7.27%- Income Yield: 1.95%As noted in the Gabelli report, a managed distribution policy may create confusion regarding the true current yield since the reported yield includes the return of capital portion. You can see the disparity above between the income yield and the distribution (reported) yield.If you are looking for a sustainable and growing dividend, you may want to consider some blue-chip dividend stocks such as these with a Free Cash Flow Payout less than 50%, 50+ years of consecutive dividend increases and a 2%+ yield:3M Co. (MMM) is a diversified global company provides enhanced product functionality in electronics, health care, industrial, consumer

Top 10 Net Payout Yield Stocks To Own For 2015: Star Bulk Carriers Corp.(SBLK)

Star Bulk Carriers Corp. operates as a shipping company providing seaborne transportation solutions in the dry bulk sector worldwide. Its vessels transport major bulks, which include iron ore, coal, and grain; and minor bulks, such as bauxite, fertilizers, and steel products. The company has an operating fleet of 15 dry bulk carriers consisting of 7 Capesize and 8 Supramax dry bulk vessels with a combined cargo carrying capacity of 1,625,945 deadweight tons. The company was incorporated in 2006 and is based in Athens, Greece.

Advisors’ Opinion:

  • [By James E. Brumley]

    It’s certainly no Safe Bulkers, Inc. (NYSE:SB) or Star Bulk Carriers Corp. (NASDAQ:SBLK), in terms or market cap or revenue. In fact, even with the drybulk shipping industry it’s a somewhat obscure name. Yet, FreeSeas Inc. (NASDAQ:FREE) may well be the stock with the most near-term potential upside, now that it’s gotten over a key technical hump.

  • [By Igor Greenwald]

    Last month, Oaktree Capital (OAK), managed by another distressed investing icon, Howard Marks, disclosed a huge 21.9% stake in Star Bulk Carriers (SBLK).

  • [By James E. Brumley]

    I’ll warn you now that if you’re a fan or shareholder of Star Bulk Carriers Corp. (NASDAQ:SBLK), then you’re not going to like what you’re about to read. Before you fly off into a tirade of “colorful” descriptions of me, however, know that this is neither a judgment call on the company itself, nor a long-term outlook. It’s simply a trading-based observation of hints that SBLK has dropped today. Fair enough? OK, let’s dig in.

Top 10 Net Payout Yield Stocks To Own For 2015: Fuel Tech Inc.(FTEK)

Fuel Tech, Inc. uses a suite of advanced technologies to provide boiler optimization, efficiency improvement, and air pollution reduction and control solutions to utility and industrial customers worldwide. It operates through two segments, Air Pollution Control Technologies and FUEL CHEM Technologies. The Air Pollution Control Technologies segment includes technologies, such as low and ultra low NOx Burners, over-fire air systems, NOxOUT and HERT selective non-catalytic reduction systems, and advanced selective catalytic reduction systems to reduce NOx emissions in flue gas from boilers, incinerators, furnaces, and other stationary combustion sources. This segment distributes its products through direct sales force and agents. The FUEL CHEM Technologies segment uses chemical processes in combination with advanced computational fluid dynamics and chemical kinetics modeling boiler modeling for the control of slagging, fouling, corrosion, opacity, and other sulfur trioxide-r elated issues in furnaces and boilers through the addition of chemicals into the furnace using Targeted In-Furnace Injection technology. This segment?s programs improve the efficiency, reliability, and environmental status of plants operating in the electric utility, industrial, pulp and paper, waste-to-energy, university, and district heating markets; and are installed on combustion units in North America, Europe, China, and India for treating various solid and liquid fuels, including coal, heavy oil, biomass, and municipal waste. It provides operational, financial, and environmental benefits to owners of boilers, furnaces, and other combustion units. The company was founded in 1987 and is headquartered in Warrenville, Illinois.

Advisors’ Opinion:

  • [By John Kell and Lauren Pollock var popups = dojo.query(“.socialByline .popC”); ]

    Fuel Tech Inc.(FTEK) said its revenue fell 9% in the fourth quarter, dragged down by declines in its air pollution control segment. Revenue and earnings fell short of market expectations. Shares dropped 18% to $5.65 premarket.

  • [By Wallace Witkowski]

    Shares of Fuel Tech Inc. (FTEK)  fell 15% to $5.86 on moderate volume. The air-pollution control technology company reported fourth-quarter earnings of 2 cents a share on revenue of $24.2 million. Only two analysts on FactSet estimated earnings averaging at 7 cents a share, while only one expected revenue of $28 million.

Top 10 Net Payout Yield Stocks To Own For 2015: Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company’s product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company’s program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company’s RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company’s lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company’s lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatmen t of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company’s lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company’s arrangement with DoD supporting the development of the Company’s Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrange ment. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company’s anti-viral therapeutic programs use the Company’s translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company’s translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA’s Animal Rule. The Co mpany’s lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company’s lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD’s invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exp osure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company’s anti-viral therapeutic programs are also focused on the development of the Company’s product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company’s lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company pau sed its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company’s PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

Advisors’ Opinion:

  • [By Rich Bieglmeier]

    It’s not every day that a stock is up 40% but still might have another 50%+ to go. However, that is the case with Sarepta Therapeutics Inc. (NASDAQ:SRPT).

  • [By Ben Levisohn]

    Shares of Sarepta Therapeutics (SRPT) and Plug Power (PLUG) are falling in after-hours trading after the two companies announced plans to sell more shares.

    Sarepta Therapeutics said it plans to sell as much as $100 million in new shares and also granted underwriters a 30-day option to buy as much as $15 million more. Plug Power announced a sale, but said the amount would depend on “market and other conditions.”

    Shares of Sarepta Therapeutics have fallen 4.5% to $38.79 at 4:49 p.m. in after-hours trading, while Plug Power has tumbled 8.7% to $6.12.

Top 10 Net Payout Yield Stocks To Own For 2015: Victory Electronic Cigarettes Corp (ECIG)

Victory Electronic Cigarettes Corporation, formerly Teckmine Industries, Inc., incorporated on May 19, 2004, is a development-stage company. As of December 31, 2011, the Company was seeking opportunities with established business entities for the merger or other form of business combination with its company. In April 2013, it acquired Victory Electronic Cigarettes LLC.

The Company may acquire assets and establish wholly owned subsidiaries in various businesses or acquire existing businesses as subsidiaries. As of December 31, 2011, it had not owned any property interests.

Advisors’ Opinion:

  • [By James E. Brumley]

    Fans and investors of American Heritage International Inc. (OTCBB:AHII) – not to mention frenemies Vapor Corp. (OTCMKTS:VPCO) and Victory Electronic Cigarettes Corp. (OTCMKTS:ECIG) – can all breathe a sigh of relief today. As it turns out, while the electronic cigarette industry is more than likely be regulated by the FDA, it’s going to be regulated in such a way that tends to favor the likes of AHII, ECIG, and VPCO.

  • [By Bryan Murphy]

    Every cigarette company from Altria Group Inc. (NYSE:MO) to Victory Electronic Cigarettes Corp. (OTCMKTS:ECIG) will want to take notice of this morning’s news from American Heritage International Inc. (OTCBB:AHII) – the young startup’s electronic cigarettes now have something else great going for them. As such, it just got a little easier for smokers to justify dumping traditional tobacco cigarettes like those made by Altria (like Marlboro) in favor of e-cigs….

Top 10 Net Payout Yield Stocks To Own For 2015: World Acceptance Corp (WRLD)

World Acceptance Corporation operates a small-loan consumer finance business in 12 states and Mexico. The Company is engaged in the small-loan consumer finance business, offering short-term small loans, medium-term larger loans, related credit insurance and ancillary products and services to individuals. As of March 31, 2012, the Company offered standardized installment loans through 1,137 offices in South Carolina, Georgia, Texas, Oklahoma, Louisiana, Tennessee, Illinois, Missouri, New Mexico, Kentucky, Alabama, Wisconsin, and Mexico. The Company serves individuals with limited access to consumer credit from banks, credit unions, other consumer finance businesses and credit card lenders. In the United States offices, the Company also offers income tax return preparation services to its customers and others.

During the fiscal year ended March 31, 2012 (fiscal 2012), the Company opened 69 new offices. In each state in which it operates and in Mexico, the Compa ny offers consumer installment loans, which are standardized by amount and maturity. The Company’s loans are consumer installment loans, which are payable in fully amortizing monthly installments with terms generally of 4 to 36 months, and all loans are pre-payable at any time without penalty. During fiscal 2012, the Company’s average originated gross loan term was approximately 12 months. As of March 31, 2012, the annual percentage rates on loans offered by the Company, which include interest, fees and other charges as calculated for the purposes of the requirements of the federal Truth in Lending Act, ranged from 24% to 204% depending on the loan size, maturity and the state, in which the loan is made. In addition, in certain states, the Company, as agent for an unaffiliated insurance company, sells credit insurance in connection with its loan transactions.

Specific allowable charges vary by state and, consistent with industry practice, the Company generally charges at or close to the maximum rates allowable under app! licable state law in those states that limit loan rates. Statutes in Texas and Oklahoma allow for indexing the maximum loan amounts to the Consumer Price Index. The Company’s loan products are pre-computed loans in which the finance charge is a combination of origination or acquisition fees, account maintenance fees, monthly account handling fee and other charges permitted by the relevant state laws.

The Company, as an agent for an unaffiliated insurance company, markets and sells credit life, credit accident and health, credit property, and unemployment insurance in connection with its loans in selected states where the sale of such insurance is permitted by law. Credit life insurance provides for the payment in full of the borrower’s credit obligation to the lender in the event of death. Credit accident and health insurance provides for repayment of loan installments to the lender, which come due during the insured’s period of income interruption resulting f rom disability from illness or injury. Credit property insurance insures payment of the borrower’s credit obligation to the lender in the event, which the personal property pledged as security by the borrower is damaged or destroyed by a covered event. Unemployment insurance provides for repayment of loan installments to the lender, which come due during the insured’s period of involuntary unemployment. The Company requires each customer to obtain specific credit insurance in the amount of the loan for all loans originated in Georgia under the Georgia Industrial Loan Act, and encourages customers to obtain credit insurance for all loans originated in South Carolina, Louisiana, Alabama and Kentucky and on a limited basis in Tennessee, Oklahoma, and Texas. Customers in those states obtain such credit insurance through the Company.

In South Carolina, Georgia, Louisiana, Kentucky and Alabama, the Company charges its borrowers for its non-file premiums in connectio n with certain loans in lieu of recording and perfecting the! Company